|
Strong start to the year for Bayer
|
30 April 2015 |
|
Bayer aspires to significantly expand Life Science businesses
|
11 March 2015 |
|
Bayer forms collaboration with academic and governmental institutions for Rivaroxaban study
|
10 February 2015 |
|
Bayer operationally strong - strategic focus on Life Science businesses
|
02 November 2014 |
|
Bayer supports World Thrombosis Day as founding global partner
|
13 October 2014 |
|
Bayer closes acquisition of consumer care business of Merck & Co., Inc., United States, for USD 14.2 billion
|
01 October 2014 |
|
Safety and sustained benefits of Adempas® from Bayer confirmed by results of long-term studies
|
08 September 2014 |
|
Bayer continues positive business development
|
30 July 2014 |
|
Bayer and Orion Corporation to develop and commercialize novel prostate cancer treatment
|
02 June 2014 |
|
Bayer HealthCare extends access to clinical trial data
|
13 May 2014 |
|
Bayer: Very successful start to 2014
|
29 April 2014 |
|
Bayer HealthCare to significantly increase production capacity in China
|
31 March 2014 |
|
Bayer to invest more than 500 million Euros for the manufacturing of hemophilia A products currently in development
|
18 March 2014 |
|
Bayer and Peking University establish new research center for translational research and drug discovery in Beijing
|
08 January 2014 |
|
Bayer plans to acquire Norwegian pharmaceutical company Algeta
|
19 December 2013 |
|
Bayer CEO Marijn Dekkers calls for greater appreciation of innovation
|
20 November 2013 |
|
Bayer continues positive business momentum
|
03 November 2013 |
|
Bayer accelerates clinical development of promising new drug candidates
|
09 October 2013 |
|
Olivier Brandicourt appointed as new CEO of Bayer HealthCare
|
30 September 2013 |
|
Bayer's investigational drug Riociguat granted FDA orphan drug designation
|
26 September 2013 |